Although the covid pandemic mitigations have been challenging, they have resulted in a perspective adjustment at MSACL that has revealed an exciting opportunity to extend the
knowledge base of the MSACL community even further into the research and clinical space ... consistent online content.
Under this new paradigm of operation, we are offering a platform of engagement to provide not only classical SCIENTIFIC CONTENT, but also to extend
the best of the MSACL NETWORKING effects -- such as those found during Booth and Poster Tours, and the Meet-a-Mentor program -- into the virtual space. SHORT COURSES are also a part of the Connect ecosystem.
Wed
May
18, 2022
Los Angeles : 10:30 AM - 12:00 PM
NEW YORK:
May 18 • 01:30 PM - 03:00 PM
LONDON:
May 18 • 06:30 PM - 08:00 PM
PARIS:
May 18 • 07:30 PM - 09:00 PM
INDIA:
May 18 • 11:00 PM - 12:30 AM
CHINA:
May 19 • 01:30 AM - 03:00 AM
SYDNEY:
May 19 • 03:30 AM - 05:00 AM
Seminar
There is no cost to register for this activity.
Beyond the Human Genome: A Million Person Precision Population Health Project
Leroy Hood, MD, PhD
Institute for Systems Biology
Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. He is currently Professor and Chrief Strategy OFficer at the Institute for Systems Biology. Dr Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA.
Dr Hood believes that a combination of big data and systems biology has the potential to revolutionize healthcare and create a proactive medical approach focused on maximizing the wellness of the individual. He coined the term "P4 medicine" in 2003.
The vision of this project is that we will develop the infrastructure to employ a data-driven approach to optimizing the health trajectory of individuals for body and brain. We have two large populations (5,000 and 10,000) that have validated this approach for body and brain health, respectively. These studies have led to us pioneering the science of wellness and prevention. This project will require the acquisition of key partners for execution, which will be delineated. We are approaching the Federal Government for funding, as we did for the first Human Genome Project. This project will lead to striking new knowledge about medicine, it will catalyze the initiation of start-up companies and it will catalyze a paradigm shift in healthcare from a disease orientation to a wellness and prevention orientation. This will catalyze the largest paradigm shift in medicine, ever.
https://www.msacl.org?header=Connect#323
1
Fri
May
20, 2022
Los Angeles : 09:00 AM - 10:30 AM
NEW YORK:
May 20 • 12:00 PM - 01:30 PM
LONDON:
May 20 • 05:00 PM - 06:30 PM
PARIS:
May 20 • 06:00 PM - 07:30 PM
INDIA:
May 20 • 09:30 PM - 11:00 PM
CHINA:
May 21 • 12:00 AM - 01:30 AM
SYDNEY:
May 21 • 02:00 AM - 03:30 AM
Seminar
Proteomics
There is no cost to register for this activity.
Moderator(s):
Christopher Shuford, Ph.D. Labcorp
Andy Hoofnagle, MD, PhD University of Washington
The Michael S. Bereman Award for Innovative Clinical Proteomics : Seeing the Forest for the Trees: Taking a Step Back to Move Proteomics Forward in the Clinical Lab
Mari DeMarco, PhD, DABCC, FACB, FCACB
University of British Columbia
Mari DeMarco, PhD, DABCC, FCACB, is a Clinical Chemist at Providence Health Care, the Research Director of Providence Research, and a Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia in Vancouver Canada. Dr. DeMarco completed her PhD in the Biomolecular Structure and Design program at the University of Washington, and a clinical chemistry fellowship at Washington University School of Medicine.
With a strong interest in bridging basic biomedical science, analytical chemistry and laboratory medicine, Dr. DeMarco’s research group focuses on building new biofluid tests for direct translation into patient care. A particular area of interest is advancing protein-based clinical diagnostics for neurodegenerative disorders, such as Alzheimer’s disease. The goal of this program of research is to ensure that these new tools make the challenging jump from research into healthcare.
Originally Presented at MSACL 2022.
Want to run a new test in your clinical lab that takes multiple days to prep, has a complicated (and costly) calibration scheme, and a detection approach so selective it could miss the analyte of interest? If that doesn’t sound appealing, you would be in the majority! While the analytical advantages of mass spectrometry resulted in it decisively displacing ligand binding methods as the gold standard approach for protein quantitation, making progress on the routine testing front has taken additional effort. Here we look at how re-evaluating the status quo in clinical proteomics has helped us take leaps forward and implement protein mass spectrometry to improve patient care.
https://www.msacl.org?header=Connect#318
Mon
May
23, 2022
Los Angeles : 10:00 AM - 11:30 AM
NEW YORK:
May 23 • 01:00 PM - 02:30 PM
LONDON:
May 23 • 06:00 PM - 07:30 PM
PARIS:
May 23 • 07:00 PM - 08:30 PM
INDIA:
May 23 • 10:30 PM - 12:00 AM
CHINA:
May 24 • 01:00 AM - 02:30 AM
SYDNEY:
May 24 • 03:00 AM - 04:30 AM
Seminar
There is no cost to register for this activity.
The Clinical Laboratory Perspective on Wellness Testing: Let’s Take a Look Under the Hood
Geoff Baird, MD, PhD
University of Washington
Geoffrey Baird, M.D., Ph.D., is a board certified pathologist at UW Medicine, and professor and acting chair of Laboratory Medicine and Pathology. He directs the Clinical Chemistry Laboratory at Harborview Medical Center.
Dr. Baird’s goal is to provide the highest quality lab services to patients in the UW community and Pacific Northwest region.
Dr. Baird earned his M.D. and Ph.D. from UC San Diego. He is board-certified in Anatomic Pathology, Clinical Pathology and Clinical Chemistry. His clinical and research interests include lab test utilization management, proteomics, tissue analysis, general laboratory medicine, pathology and pathophysiology of organ systems and anatomic pathology.
As medical science continues to make gains in the elucidation of disease pathophysiology and the discovery of cures , some have questioned the value of dedicating dwindling financial resources to maintaining wellness rather than to fighting disease per se. While both approaches are meritorious and complementary, neither approach is alone sufficient to ensure the health of a population. One major problem with the focus on wellness is the Bayesian dilemma that the positive predictive value of clinical laboratory testing in apparently healthy people is often low, as the specificities of few clinical tests are high enough to ensure that most positive results are true. The impact of this dilemma on laboratory-based wellness approaches will be discussed.
https://www.msacl.org?header=Connect#319
3
Thu
Aug
18, 2022
Los Angeles : 09:00 AM - 10:00 AM
NEW YORK:
Aug 18 • 12:00 PM - 01:00 PM
LONDON:
Aug 18 • 05:00 PM - 06:00 PM
PARIS:
Aug 18 • 06:00 PM - 07:00 PM
INDIA:
Aug 18 • 09:30 PM - 10:30 PM
CHINA:
Aug 19 • 12:00 AM - 01:00 AM
SYDNEY:
Aug 19 • 02:00 AM - 03:00 AM
Seminar
Supported by an Open Unrestricted Educational Grant
provided by
There is no cost to register for this activity.
Jennifer Van Eyk, PhD
Cedars-Sinai Heart Institute
Jennifer Van Eyk, PhD, is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Dr. Van Eyk's laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.